Cibc World Market Inc. Makes New $1.23 Million Investment in Ascendis Pharma A/S $ASND

Cibc World Market Inc. bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 6,168 shares of the biotechnology company’s stock, valued at approximately $1,226,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. First Horizon Advisors Inc. purchased a new stake in Ascendis Pharma A/S during the second quarter worth about $41,000. Jones Financial Companies Lllp grew its position in shares of Ascendis Pharma A/S by 57.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 83 shares during the period. Hantz Financial Services Inc. grew its position in shares of Ascendis Pharma A/S by 291.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 262 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 115.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock worth $95,000 after purchasing an additional 256 shares during the last quarter. Finally, Toth Financial Advisory Corp lifted its stake in Ascendis Pharma A/S by 33.7% in the third quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 150 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Royal Bank Of Canada increased their price objective on Ascendis Pharma A/S from $245.00 to $250.00 and gave the company an “outperform” rating in a report on Tuesday, January 20th. Bank of America increased their price target on Ascendis Pharma A/S from $246.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Wedbush boosted their price objective on Ascendis Pharma A/S from $240.00 to $273.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Morgan Stanley reiterated an “overweight” rating and set a $256.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday. Finally, Wells Fargo & Company boosted their price target on shares of Ascendis Pharma A/S from $322.00 to $330.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $284.00.

Ascendis Pharma A/S Price Performance

ASND opened at $216.32 on Tuesday. The firm has a market capitalization of $13.41 billion, a P/E ratio of -49.16 and a beta of 0.44. Ascendis Pharma A/S has a one year low of $124.06 and a one year high of $242.00. The company has a fifty day moving average price of $215.04 and a 200-day moving average price of $205.71.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The company had revenue of $290.38 million during the quarter, compared to the consensus estimate of $285.35 million. On average, analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.